Oligopeptide-1

What is Oligopeptide-1?

Oligopeptide-1 is the cosmetic-ingredient name for human epidermal growth factor (EGF). The naming deserves unpacking, because it is the source of most of the confusion around this ingredient and because the label on a bottle rarely says 'EGF' at all. In the EU's CosIng inventory the entries are prefix-qualified. sh-Oligopeptide-1 (inventory reference 87479, dated December 2011) is described as a single-chain recombinant human peptide produced by fermentation in E. coli, containing a maximum of 53 amino acids which may carry disulfide bonds and/or sugar, with a listed function of skin conditioning. rh-Oligopeptide-1 (reference 84391) is described the same way but produced in either E. coli or Pichia pastoris and specified at 53 amino acids. A later entry, sh-Oligopeptide-1 SP (reference 98224, dated April 2020), is a 53-amino-acid fragment produced synthetically to be identical to a portion of human epidermal growth factor. The prefixes follow the industry convention in which sh- denotes synthetic human and rh- denotes recombinant human. The word 'oligopeptide' is doing a lot of work it cannot support. Human EGF is 53 amino acids and roughly 6.2 kDa, held in shape by three disulfide bonds — in any other context that is a small protein, not an oligopeptide, and the distinction is not pedantic. Molecular size is the central obstacle to topical delivery, and a naming convention that makes a 6 kDa protein sound like a short peptide quietly obscures the main reason to doubt that it works through intact skin. What EGF does biologically is not in dispute. Stanley Cohen's discovery of it won a share of the 1986 Nobel Prize in Physiology or Medicine, it is one of the best-characterised mitogens in biology, and recombinant EGF has a legitimate therapeutic record in wound healing. The disputes are narrower and sharper: whether cosmetic-grade material retains bioactivity, whether it penetrates, and whether applying a potent mitogen to sun-damaged skin is wise.

What Oligopeptide-1 Is Investigated For

There is a sharp split between where EGF has real evidence and where it is actually sold. The real evidence is in wound healing and post-procedure recovery: recombinant human EGF has a genuine therapeutic record in chronic ulcers, and a split-face randomised controlled study of EGF ointment after fractional ablative resurfacing reported benefit for healing and post-inflammatory hyperpigmentation. Those studies use medical-grade material on compromised skin, where the barrier that normally blocks a 6 kDa protein is temporarily absent. The cosmetic use case — a serum applied to intact facial skin for anti-aging — is where the evidence thins dramatically. The most informative studies are the ones that bypass the barrier instead of trusting it. A randomised split-face trial of a soluble micro-spicule EGF cream against a cream containing EGF alone found the micro-spicule formulation significantly better on dermal depth and density at 4 and 8 weeks. That is a useful result for a different reason than its authors emphasised: if penetration-enhancing delivery beats plain EGF cream, the plain cream is the weak arm. A separate double-blind split-face trial in 52 Korean women found that a cross-linked hyaluronic-acid microneedle patch containing EGF outperformed the patch alone — again, with the needles doing the delivery work. The skeptical case is not merely absence of evidence. Martínez-Carpio's 2023 review in Cutaneous and Ocular Toxicology examined the published clinical trials using sh-Oligopeptide-1 as an EGF equivalent and concluded that the preclinical bioactivity of the molecule has not been proven, that sh-Oligopeptide-1 is not a functional EGF, and that active EGF is a potent unauthorised drug rather than a cosmetic. A 2026 randomised pilot comparing a recombinant EGF (oligopeptide-1) serum with a human-derived growth factor serum in 20 women favoured the recombinant arm on some investigator-rated outcomes, but global wrinkle severity changed minimally in both groups — a modest finding from a small, short, female-only pilot that its own authors flag as limited.

History & Discovery

Epidermal growth factor was discovered by Stanley Cohen at Washington University in the early 1960s, during work on nerve growth factor with Rita Levi-Montalcini. Cohen observed that extracts of mouse submaxillary gland caused newborn mice to open their eyes and erupt teeth earlier than expected, traced the effect to a specific protein, and characterised it — work that shared the 1986 Nobel Prize in Physiology or Medicine with Levi-Montalcini. Human EGF was subsequently sequenced as a 53-residue protein with three disulfide bonds, and its receptor became one of the most intensively studied molecules in oncology. Recombinant production via E. coli and later Pichia pastoris fermentation made the protein available in quantity from the 1980s onward, and its first serious clinical applications were therapeutic rather than cosmetic: corneal wound healing, surgical wounds, and especially diabetic foot ulcers, where topical and intralesional rhEGF products reached approval in several countries. Cuba's Heberprot-P, an intralesional rhEGF for diabetic foot ulcer, is the best-known of these. The cosmetic pivot came through South Korea in the 2000s, where EGF serums became a defining category of the K-beauty export boom, and from there into global skincare. Regulatory nomenclature followed commerce rather than leading it: sh-Oligopeptide-1 and rh-Oligopeptide-1 appear in the EU CosIng inventory with source dates in 2011, and sh-Oligopeptide-1 SP was added in 2020. The category's most consequential regulatory moment came on 10 January 2019, when China's National Medical Products Administration published a FAQ stating that EGF was banned as a cosmetic ingredient on efficacy and safety grounds — barring it from formulas, labels and advertising alike, in what was then one of the world's largest growth markets for the ingredient. The same guidance carved out a distinct, IECIC-listed oligopeptide-1 as permitted, provided filings demonstrate the material is not EGF. Four years later Martínez-Carpio's review in Cutaneous and Ocular Toxicology arrived at a comparably sceptical conclusion from the scientific rather than regulatory direction, framing the question in its title as 'risk or fraud?'. Outside China the ingredient remains permitted and widely sold, with no published CIR or SCCS safety assessment either supporting or contradicting it.

How It Works

Epidermal growth factor is one of the body's own instructions to skin cells to divide and rebuild. When skin is wounded, EGF levels rise locally, keratinocytes multiply, and the wound closes. The idea behind EGF skincare is to supply that same signal on purpose. The difficulty is that EGF is a fairly large protein and healthy skin is specifically built to keep large proteins out — so the signal has to get past a barrier designed to stop it, and it mostly does not.

Human EGF is a 53-amino-acid, roughly 6.2 kDa protein stabilised by three intramolecular disulfide bonds, which define the fold required for receptor binding. It binds the epidermal growth factor receptor (EGFR, ErbB1/HER1), a receptor tyrosine kinase expressed abundantly on basal keratinocytes and, at lower density, on dermal fibroblasts. Ligand binding drives receptor dimerisation and trans-autophosphorylation, recruiting adaptor proteins and activating the RAS-RAF-MEK-ERK and PI3K-AKT cascades. Downstream, the output is proliferative and migratory: keratinocyte proliferation and lateral migration, which is why EGF accelerates re-epithelialisation of wounds; modulation of matrix metalloproteinase and collagen expression in fibroblasts, which is the basis of the anti-aging claim and is more equivocal, since EGFR activation can increase MMP-1 as well as stimulate matrix synthesis; and effects on melanogenesis, with one dermatologic surgery study reporting that EGF and EGF signalling attenuate laser-induced melanogenesis, which is the mechanistic story behind the post-inflammatory hyperpigmentation claim. The delivery problem is where the mechanism meets reality. The stratum corneum is a lipid-embedded barrier that passively admits small, moderately lipophilic molecules — conventionally cited as under about 500 daltons — and excludes hydrophilic macromolecules. EGF is more than ten times that size and hydrophilic. Published attempts to make topical EGF work therefore cluster around circumventing the barrier rather than around the biology: dissolving micro-spicules, cross-linked hyaluronic-acid microneedle patches, transfersomal emulgels, liposomal and nanostructured lipid carriers, and chitosan microencapsulation. The comparative results in that literature are informative about the base case, because formulations designed to penetrate consistently outperform formulations that are not. It is worth stating plainly that none of this mechanistic description establishes that a retail serum delivers active EGF to a living keratinocyte. The receptor biology is textbook; the delivered dose is the unmeasured variable.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Oligopeptide-1:

• 01Whether cosmetic-grade sh-Oligopeptide-1 is biologically active at all. The 2023 Cutaneous and Ocular Toxicology review concluded the preclinical bioactivity of the molecule has not been proven, and no independent potency verification of retail material has been published. This is the gap everything else depends on.
• 02Quantified penetration from conventional vehicles. No study has measured how much intact, correctly folded EGF reaches viable epidermis from a commercial serum applied to intact skin — the single number that would settle the category.
• 03Long-term safety of chronic EGFR stimulation in photodamaged skin. The concern is mechanistically coherent and completely unstudied in a cosmetic-use population; no regulatory body has published a formal safety assessment either way, and the one regulator to rule on it banned the ingredient.
• 04Isolated efficacy. Every reasonably designed cosmetic trial has confounded EGF with its delivery system or with co-formulated actives, so no study isolates what EGF itself contributes at cosmetic concentrations.
• 05Stability and shelf life in finished products. Retail serums sold unrefrigerated with long shelf lives make an implicit stability claim that is rarely substantiated by published data on disulfide integrity or retained activity over time.
• 06Reconciling the regulatory split. China banned EGF in cosmetics in 2019 on efficacy and safety grounds; the EU and US permit it without a published assessment. No body has attempted to reconcile those positions on the evidence, which leaves consumers in different markets facing opposite official conclusions about the same molecule.
• 07Source comparability. Whether E. coli, Pichia pastoris, synthetic and plant-expressed variants are clinically equivalent has only been probed by a single 20-person pilot whose perception findings the authors themselves call exploratory.
• 08Dose-response. No study has established a concentration below which EGF does nothing or above which it does more, which makes any labelled concentration uninterpretable even where one is disclosed.

Forms & Administration

Sold almost exclusively as a topical cosmetic: serums, ampoules, essences and post-procedure creams, usually listing sh-Oligopeptide-1 or rh-Oligopeptide-1 in the ingredient deck rather than EGF. Applied once or twice daily to cleansed skin, typically before heavier occlusive layers. Delivery-enhanced formats — dissolving microneedle patches and micro-spicule creams — exist and carry the better controlled evidence, because they address the molecule's central problem rather than ignoring it. Medical-grade recombinant human EGF ointments and gels are separate products used for wound healing and post-laser recovery under clinical supervision, and in several countries are regulated as drugs rather than cosmetics. Finished cosmetic products rarely disclose concentration in verifiable units and no retail potency assay exists, so stated amounts should be treated as marketing rather than specification. There is no legitimate injectable cosmetic form.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Oligopeptide-1 is a cosmetic ingredient in most jurisdictions and a banned cosmetic ingredient in China. It is not FDA-approved to treat or prevent any condition. Medical-grade recombinant human EGF products used for wound healing are regulated separately as drugs in several countries and are not interchangeable with cosmetic serums.

Timeline of Effects

Common Questions

Who Oligopeptide-1 Is NOT For

Drug & Supplement Interactions

No systemic pharmacological interactions are documented or expected. Absorption of intact 6.2 kDa protein from topical cosmetic use on undamaged skin is negligible, so meaningful plasma levels and interactions with oral or injected medications are not a realistic concern. The relevant interaction space is entirely topical and formulation-level. The interactions that matter are chemical rather than pharmacological. Low-pH actives degrade the protein: high-concentration L-ascorbic acid, strong alpha-hydroxy and beta-hydroxy acids, and acidic peels should not share a layer or an application window. Protease-containing enzymatic exfoliants are an obvious hazard to any protein active. Benzoyl peroxide is oxidising and poorly compatible. Niacinamide, hyaluronic acid, ceramides and occlusives are unproblematic, and retinoids are usually described as complementary rather than conflicting — though the combination of a retinoid's epidermal turnover with a mitogenic growth factor has not been studied for either efficacy or safety. Two clinical contexts deserve specific mention. Patients on EGFR-inhibitor therapy — cetuximab, panitumumab, erlotinib, osimertinib and the rest — develop characteristic acneiform rash precisely because the drug blocks the pathway this ingredient stimulates. Topical EGF in that setting is pharmacologically contradictory to the systemic treatment, and anything applied to the skin of a patient on an EGFR inhibitor should be cleared with their oncology team. Separately, systemic corticosteroids and immunosuppressants alter the wound-healing environment in which post-procedure EGF use is intended to act, which matters for the one application with decent evidence behind it.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions